MRD Testing: 3 Tools You Should Be Using Now to Improve Oncology Care

How to Predict Better Treatment Outcomes through Advancements in MRD Testing

Measurement of residual disease (MRD) is one of the most reliable predictors of treatment outcomes for patients with leukemia, lymphoma, and myeloma. Because of this, global central laboratories like Q2 Solutions will have an increasingly important role to play in MRD testing.

In this complimentary insight brief you'll learn how 3 key technologies – Next Generation Sequencing, Flow Cytometry, and Polymerase Chain Reaction – help pharmaceutical and biotechnology companies predict better treatment outcomes through MRD testing.

Contact us today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.

About the Authors:
Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions
Mark Edinger, Director, Scientific Advisor, Flow Cytometry
Victor Weigman, Ph.D., Director, Translational Genomics
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics
Alan Wookey, B.Sc., Scientific Advisor, Oncology and Companion Diagnostics
Franklin Sedarat, M.D., M.Sc., FCAP, Director of Hematopathology
Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Q2 Solutions Central Laboratory Services

Optimized logistics, deeper science, better insights

Q2 Solutions central laboratory services in China

Local Chinese market knowledge with global experience to support your local, regional or global development program

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Read More